文献速递垂体与肾上腺疾病

奥西洛司他在副肿瘤性库欣综合征中的疗效与安全性:法国真实世界多中心研究

Efficacy and Safety of Osilodrostat in Paraneoplastic Cushing Syndrome: A Real-World Multicenter Study in France.
PubMed 文献 · J Clin Endocrinol Metab · 2023-01-01

该回顾性多中心真实世界研究纳入33例重度/极重度高皮质醇血症的副肿瘤性库欣综合征/异位促肾上腺皮质激素综合征(PNCS/EAS)患者,评估奥西洛司他的疗效与安全性。奥西洛司他快速降低24小时尿游离皮质醇,改善血压、高血糖和低钾血症,总体耐受良好,肾上腺功能不全为主要副作用。

要点

  • 在11例一线单药治疗患者中,中位24小时尿游离皮质醇从26倍正常上限降至0.11倍正常上限(P < .001)。
  • 9例一线单药治疗患者在2周(中位)内实现24小时尿游离皮质醇正常化。
  • 33例患者中8例报告3-4级肾上腺功能不全。

核心结论

  • 奥西洛司他是治疗伴重度/极重度高皮质醇血症的PNCS/EAS的快速有效疗法。
  • 奥西洛司他总体耐受良好,肾上腺功能不全为主要副作用。

研究设计与样本

  • 回顾性、多中心、真实世界研究,纳入33例伴重度/极重度高皮质醇血症的PNCS/EAS患者。
  • 患者于2019年5月至2022年3月期间接受奥西洛司他,中位初始剂量4 mg/天(范围1-60),最大剂量20 mg/天(范围4-100)。
  • 用药方案包括滴定(n = 6)、阻断-替代(n = 16)或先滴定后阻断-替代(n = 11)。

主要发现

  • 11例一线单药治疗患者中,中位24小时尿游离皮质醇从26倍正常上限(范围2.9-659)降至0.11倍正常上限(范围0.08-14.9),P < .001。
  • 上述11例中9例在2周(中位)内实现24小时尿游离皮质醇正常化。
  • 13例既往接受经典类固醇生成抑制剂治疗的患者中10例未控制,其二线奥西洛司他单药治疗使24小时尿游离皮质醇从2.6倍正常上限(范围1.1-144)显著降至0.22倍正常上限(范围0.12-0.66),P < .01。
  • 9例接受奥西洛司他联合另一种抗皮质醇药物治疗的患者,24小时尿游离皮质醇从11.8倍正常上限(范围0.3-247)降至0.43倍正常上限(范围0.33-2.4),P < .01。
  • 主要临床症状/合并症显著改善,包括血压、高血糖和低钾血症改善,允许停用或减少患者治疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Prospective studies have demonstrated the efficacy of osilodrostat in Cushing disease. No study has evaluated osilodrostat in a series of patients with paraneoplastic Cushing syndrome/ectopic adrenocorticotropin syndrome (PNCS/EAS). OBJECTIVE: This work aimed to evaluate in France the real-world efficacy and safety of osilodrostat in patients with PNCS/EAS. METHODS: A total of 33 patients with PNCS/EAS with intense/severe hypercortisolism were involved in this retrospective, multicenter, real-world study. Patients received osilodrostat between May 2019 and March 2022 at a median initial dose (range) of 4 mg/day (1-60) and maximum dose, 20 mg/day (4-100), first under patient then cohort temporary authorizations and after marketing authorization. Regimens used titration (n = 6), block and replace (n = 16), or titration followed by block and replace (n = 11). RESULTS: In 11 patients receiving osilodrostat as first-line monotherapy, median 24-hour urinary free cortisol (24h-UFC) decreased dramatically (from 26 × upper limit of normal [ULN; 2.9-659] to 0.11 × ULN [0.08-14.9]; P < .001). In 9 of them, 24h-UFC normalization was achieved in 2 weeks (median). Thirteen additional patients were previously treated with classic steroidogenesis inhibitors but 10 of these 13 were not controlled. In these patients, osilodrostat monotherapy, used as second line, induced a significantly decreased of 24h-UFC (from 2.6 × ULN [1.1-144] to 0.22 × ULN [0.12-0.66]; P < .01). Nine additional patients received osilodrostat in combination with another anticortisolic drug, decreasing 24h-UFC from 11.8 × ULN (0.3-247) to 0.43 × ULN (0.33-2.4) (P < .01). In parallel, major clinical symptoms/comorbidities improved dramatically with improvement in blood pressure, hyperglycemia, and hypokalemia, allowing the discontinuation or dose reduction of patient treatments. Adrenal insufficiency (grade 3-4) was reported in 8 of 33 patients. CONCLUSION: Osilodrostat is a rapidly efficient therapy for PNCS/EAS with severe/intense hypercortisolism. Osilodrostat was generally well tolerated; adrenal insufficiency was the main side effect.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Dormoy A, Haissaguerre M, Vitellius G, et al. Efficacy and Safety of Osilodrostat in Paraneoplastic Cushing Syndrome: A Real-World Multicenter Study in France. J Clin Endocrinol Metab. 2023. PMID: 36470583. doi:10.1210/clinem/dgac691

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。